Skip to main content

Table 3 Genotype Frequencies and Pulmonary Function of Progressive and Non-progressive Subgroups of IPF Patients

From: Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression

 

Progressive Group

Non-Progressive Group

Patients, n

49

72

Age, y (range)

70.51 ± 9.3

69.95 ± 8.9

Gender, F/M (%)

12/37 (24.5/75.5)

26/46 (36.1/63.9)

FcγRIIa Genotypes, n (%)

RR

16 (32.7)

32 (44.4)

 

RH

19 (38.8)

32 (44.4)

 

HH

14 (28.6)

8 (11.1)

 

χ2 = 6.13, df2, p = 0.047

FcγRIIa Alleles, n (%)

R

51 (52.0)

96 (66.7)

 

H

47 (48.0)

48 (33.3)

 

p = 0.023, OR 1.84, 95% CI 1.09-3.12

FEV 1 , L (% predicted)

2.29 ± 0.6 (90.3 ± 20.9)

2.19 ± 0.6 (89.2 ± 18.8)

FVC, L (% predicted)

2.81 ± 0.7 (86.8 ± 21.1)

2.86 ± 0.8 (91.7 ± 17.8)

FEV 1 /VC, % predicted

81.96 ± 9.9

77.05 ± 9.5

TLC, L (% predicted)

4.33 ± 1.0 (71.5 ± 15.6)

4.43 ± 1.0 (76.8 ± 13.5)

D L CO , ml/min/mmHg (% predicted)

4.13 ± 1.3 (52.2 ± 16.3)

4.18 ± 1.3 (53.8 ± 14.3)

K CO , ml/min/mmHg/L (% predicted)

1.08 ± 0.3 (82.7 ± 22.8)

1.10 ± 0.3 (81.7 ± 22.8)

  1. Disease progression groups were determined based on changes in FVC or DL CO. Progressive group displayed a ≥10% decrease in FVC and/or a ≥15% decrease in DL CO 12 months after baseline measurements. Values as mean ± SD. Abbreviations: IPF: idiopathic pulmonary fibrosis; DL CO: Diffusing capacity of the lung for carbon monoxide; KCO: DL COcorrected for lung volume.